Allarity Therapeutics Files 8-K

TL;DR

ALLR filed an 8-K, likely with financial updates. Keep an eye out for details.

AI Summary

On October 9, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing signals that Allarity Therapeutics is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational risks.

Key Players & Entities

• Allarity Therapeutics, Inc. (company) — Registrant
• October 9, 2024 (date) — Date of earliest event reported
• 001-41160 (other) — Commission File Number
• 24 School Street, 2nd Floor, Boston, MA 02108 (location) — Principal Executive Offices Address

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock , par value $0.0001 per share ALLR The Nasdaq Stock Mark
• $1.00 — intained a minimum closing bid price of $1.00 per share required for continued listin

Filing Documents

• allr20241010_8k.htm (8-K) — 30KB
• ex_731348.htm (EX-99.1) — 10KB
• atlogosmall.jpg (GRAPHIC) — 6KB
• 0001437749-24-031059.txt ( ) — 188KB
• allr-20241009.xsd (EX-101.SCH) — 3KB
• allr-20241009_def.xml (EX-101.DEF) — 12KB
• allr-20241009_lab.xml (EX-101.LAB) — 16KB
• allr-20241009_pre.xml (EX-101.PRE) — 12KB
• allr20241010_8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. As previously reported, on June 18, 2024, Allarity Therapeutics, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") therein stating that for the 30 consecutive business day period between May 6, 2024 through June 17, 2024, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). On October 9, 2024, the Company received a letter from the Listing Qualifications Staff of Nasdaq informing the Company that for the 20 consecutive business day period between September 11, 2024 through October 9, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is closed. On October 10, 2024, the Company issued a press release announcing its compliance with the Bid Price Rule. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated October 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: October 11, 2024 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR